IGF-1 LR3

IGF-1 LR3, also known as Long R3 IGF-1 or LR3-IGF-1, is a modified form of insulin-like growth factor 1 classified as a growth factor. This research compound has been engineered with an extended half-life compared to native IGF-1, making it valuable for laboratory studies investigating cellular growth mechanisms. The mechanism of action involves IGF-1 LR3 binding to the IGF-1 receptor with high affinity, subsequently activating intracellular signalling pathways such as the PI3K/Akt pathway. This activation leads to increased protein synthesis and cell proliferation, particularly observed in muscle and bone tissues in research models. The extended half-life characteristic allows for prolonged receptor activation compared to native IGF-1, providing researchers with a more sustained experimental window. Studies indicate several primary research effects in laboratory models, including increased muscle-regulatory pathways, enhanced recovery from exercise procedures, improved bone density measurements, potential reduction in body fat composition, and increased cellular proliferation rates. These effects make IGF-1 LR3 particularly relevant for research into growth factor biology, tissue regeneration, and metabolic processes. The current evidence grade is classified as C, reflecting that most available data comes from animal studies and extrapolation from broader IGF-1 research. Limited human trials have been conducted specifically on IGF-1 LR3, indicating that further human studies are needed to confirm efficacy and safety profiles, particularly regarding long-term effects. This evidence limitation makes IGF-1 LR3 particularly suitable for controlled laboratory research environments where researchers can contribute to the expanding knowledge base surrounding this growth factor.